SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Publication of UK Annual Report and Notice of Annual General Meeting 
 
   Oxford, UK, and Cambridge, MA, US, 14 May 2019 - Summit Therapeutics plc 
(AIM: SUMM, NASDAQ: SMMT), announces that its Annual Report and Accounts 
for the year ended 31 January 2019, together with the Notice of Annual 
General Meeting, have today been sent to shareholders. Copies of both 
documents are available on the Company's website, 
https://www.globenewswire.com/Tracker?data=WSzkyM1SroSaq542ax0o3ngb3Z3YBuY-BqtzgIFQ_-saftEWNo01_SfQk2WaRJquD_9_b91lqng5ehgMJ-dBd96w7phKFLuAptdHsP8Ynhg= 
www.summitplc.com. 
 
   The Annual General Meeting will be held at 10:00am BST on 19 June 2019 
at Pewterers' Hall, Oat Lane, London, EC2V 7DE. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)          Tel:               44 (0)1235 443 951 
Michelle Avery (US office)                                            +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                       Tel:              +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                       Tel:              +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer, Corporate Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)       Tel:              +44 (0)20 7332 2500 
Phil Walker / Dominic Wilson 
MSL Group (US)                                  Tel:                  +1 781 684 6557 
                                                           mailto:summit@mslgroup.com 
Jon Siegal                                                        summit@mslgroup.com 
                                                       ------------------------------ 
 
Consilium Strategic Communications (UK)         Tel:              +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson /     mailto:summit@consilium-comms. 
                                                       com 
                                                       summit@consilium-comms.com 
                                                       ------------------------------ 
Lindsey Neville 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

May 14, 2019 12:31 ET (16:31 GMT)

Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025

Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025